American Association for Cancer Research
Browse
10780432ccr152226-sup-155522_1_supp_3273424_nzgznk.pptx (283.26 kB)

Supplemantary Figure S2 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma

Download (283.26 kB)
figure
posted on 2023-03-31, 18:49 authored by Suhendan Ekmekcioglu, Michael A. Davies, Keiji Tanese, Jason Roszik, Myung Shin-Sim, Roland L. Bassett, Denái R. Milton, Scott E. Woodman, Victor G. Prieto, Jeffrey E. Gershenwald, Donald L. Morton, Dave S. Hoon, Elizabeth A. Grimm

Clinical outcomes by CD74 categorical expression (both number and intensity) in tumor cells (A) in discovery and (B) in validation datasets of stage III melanoma patients. Kaplan-Meier analyses are shown for OS and RFS.

Funding

MD Anderson Cancer Center

NIH

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

The University of Texas, M.D. Anderson Cancer Center Melanoma Moon Shots Program

History

ARTICLE ABSTRACT

Purpose: Inflammatory marker expression in stage III melanoma tumors was evaluated for association with outcome, using two independent cohorts of stage III melanoma patients' tumor tissues.Experimental Design: Fifteen markers of interest were selected for analysis, and their expression in melanoma tissues was determined by immunohistochemistry. Proteins associating with either overall survival (OS) or recurrence-free survival (RFS) in the retrospective discovery tissue microarray (TMA; n = 158) were subsequently evaluated in an independent validation TMA (n = 114). Cox proportional hazards regression models were used to assess the association between survival parameters and covariates, the Kaplan–Meier method to estimate the distribution of survival, and the log-rank test to compare distributions.Results: Expression of CD74 on melanoma cells was unique, and in the discovery TMA, it associated with favorable patient outcome (OS: HR, 0.53; P = 0.01 and RFS: HR, 0.56; P = 0.01). The validation data set confirmed the CD74 prognostic significance and revealed that the absence of macrophage migration inhibitory factor (MIF) and inducible nitric oxide synthase (iNOS) was also associated with poor survival parameters. Consistent with the protein observation, tumor CD74 mRNA expression also correlated positively (P = 0.003) with OS in the melanoma TCGA data set.Conclusions: Our data validate CD74 as a useful prognostic tumor cell protein marker associated with favorable RFS and OS in stage III melanoma. Low or negative expression of MIF in both TMAs and of iNOS in the validation set also provided useful prognostic data. A disease-specific investigation of CD74's functional significance is warranted, and other markers appear intriguing to pursue. Clin Cancer Res; 22(12); 3016–24. ©2016 AACR.

Usage metrics

    Clinical Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC